The Virchow Prize 2026 Awarded for Pioneering Work on Ebola, Advancing Global Epidemic Preparedness and Fostering Global Solidarity
3.6.2026 12:37:54 CEST | news aktuell GmbH | Press release
Jean-Jacques Muyembe and Peter Piot are being honored with the international award of €500,000 for exceptional life-long leadership spanning five decades since the first outbreak of Ebola

Berlin, Germany – June 2, 2026: The Virchow Prize 2026 has been jointly awarded to Jean‑Jacques Muyembe and Peter Piot for their pioneering and enduring leadership in the discovery, control, and understanding of epidemic threats, and for advancing equitable, multilateral cooperation and governance that have fundamentally strengthened global preparedness and solidarity in the face of infectious disease outbreaks.
The announcement was made today by the Virchow Foundation which is granting the annual award. The selection of the laureates by the independent Virchow Prize Committee was preceded by a nomination period that ended on February 28, followed by a three-month deliberation period.
This moment resonates with particular historical gravity: 2026 marks both fifty years since the emergence of Ebola and a renewed confrontation with the virus through the current outbreak and unpreparedness.
According to the committee, the careers of Jean‑Jacques Muyembe and Peter Piot are anchored in a defining moment of modern infectious disease history: the first identified Ebola outbreak in 1976. Their collaboration demonstrated the necessity of crossing contextual, disciplinary and geographic boundaries, highlighting both the potential and the inequities inherent in global health partnerships. Over the decades, both Muyembe and Piot have worked – partly closely together, partly independent from each other in complementary ways – to transform epidemic research in an exemplary manner, firmly rooted in equity, reciprocity, and shared leadership.
Taken together, the laureates’ contributions illustrate a continuum that is central to advancing health for all: from discovery to delivery, from local response to global coordination, from emergency action to long-term system strengthening. Their work has directly improved the ability to detect, understand, and control deadly outbreaks, while also influencing broader frameworks for addressing global health challenges in a manner that is equitable and inclusive.
By awarding the Virchow Prize 2026 equally to Muyembe and Piot, their scientific achievements and their commitment to strengthening health systems and fostering global solidarity are honored. The laureates’ work embodies Rudolf Virchow’s legacy that health is inseparable from social organisation, governance, and collective responsibility.
Full Article and detailed Virchow Prize Committee jury rationale at www.virchowprize.org/vp2026
Contact: Virchow Foundation | Dorotheenstr. 83 | DE-10117 Berlin, Germany | press@virchow.foundation
Images

About news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Grünenthal strengthens its Genetic Medicine Capabilities and joins the Cluster for Nucleic Acid Therapeutics Munich16.7.2026 10:42:31 CEST | Press release
Aachen, Germany, 16 July 2026 – Grünenthal announced today that the company has joined the Cluster for Nucleic Acid Therapeutics Munich (CNATM), a Munich-centred innovation network that brings together leading universities, research institutions, biotech companies and industry partners to accelerate next-generation nucleic acid therapeutics into innovative treatments that can make a meaningful difference for patients
They’re really going for it: emporia launches the first 5G smartphone with a screen warranty15.7.2026 08:40:22 CEST | Press release
Better safe than sorry: the emporiaSMART.8 with Smartcover and rubber protectors
FEV collaborates with Microsoft on efficient AI model approach for in car applications built on NVIDIA9.7.2026 11:05:00 CEST | Press release
Aachen – FEV is collaborating with Microsoft to integrate powerful, in-vehicle Generative AI capabilities built on NVIDIA GPU-accelerated compute and AI model microservices. The cooperation aims to enable multimodal voice, text, and gesture interactions directly in the vehicle – independent of a permanent Internet connection.
Acrobat Studio og Acrobat KI-assistent: den nye generasjonen KI-støttet produktivitet – nå også på norsk8.7.2026 15:08:48 CEST | Press release
SAN JOSE, Calif. - 8. juli 2026 - Adobe utvider tilgjengeligheten til Acrobat Studio og Acrobat KI-assistenten i Norge. Nå er de KI-støttede funksjonene for produktivitet og kreavtivitet også tilgjengelige på norsk, og kan dermed brukes av brukere på lokalt språk. Acrobat Studio kombinerer Adobe Acrobat Pro, Adobe Express Premium og smarte KI-assistenter. Acrobat KI-assistent er også tilgjengelig som et separat tillegg for alle Adobe Acrobat-produkter (Acrobat Reader, Acrobat Standard og Acrobat Pro) – et fleksibelt alternativ for alle som ønsker å bruke KI-støttede funksjoner kun når de arbeider med dokumenter. Begge disse tilbudene gjør det mulig for brukere å raskere samle inn informasjon i PDF-er og Office-dokumenter, opprette innhold og effektivisere arbeidsflyten. Acrobat Studio og Acrobat KI-assistenten markerer et viktig trinn i utviklingen av PDF-filen, som har blitt standarden for viktige dokumenter siden den ble lansert av Adobe i 1993. Acrobat utvikler seg fra et ledende pr
Grünenthal receives FDA Orphan Drug and Rare Pediatric Disease Designations for Tegacorat for the Treatment of Duchenne Muscular Dystrophy8.7.2026 10:37:04 CEST | Press release
Aachen, 08 July 2026 – Grünenthal announced today that its investigational compound tegacorat (GRM-01) received Orphan Drug and Rare Pediatric Disease Designations from the US Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy (DMD).
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom